Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE003 (CAN) (Dr. Okafor)
· consented 2022-12-12
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-23 (study day 123); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-08-14 (study day 236); relationship: Y
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-06 (study day 350); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-01-13 (study day 388); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-01-25 (study day 400); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.